Boston Pharmaceuticals to Present Phase 2 Biopsy Results for Long-Acting, Once-Monthly FGF21 Analogue Efimosfermin Alfa (BOS-580) in F2 and F3 MASH in Late-Breaking Oral Presentation at AASLD, The Liver Meeting® 2024

Autor: Boston Pharmaceuticals
Zdroj: Business Wire (English). 10/16/2024.
Abstrakt: Boston Pharmaceuticals, a clinical-stage biopharmaceutical company developing differentiated molecules addressing serious liver diseases, today announced it will present key results including histologic responses from a Phase 2 study evaluating the safety and efficacy of the investigational agent, efimosfermin alfa (formerly known as BOS-580), in participants with stage F2 and F3 fibrosis due to metabolic dysfunction-associated steatohepatitis (MASH) as a late-breaking oral presentation at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® (Nov. 15-19, 2024 in San Diego). [ABSTRACT FROM PUBLISHER]
Databáze: Regional Business News
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje